This site is intended for healthcare professionals

EU approves Keytruda plus chemo for metastatic triple-negative breast cancer.- Merck Inc

Read time: 1 mins
Last updated:23rd Oct 2021
Published:23rd Oct 2021
Merck Inc announced that the European Commission (EC) has approved Keytruda (pembrolizumab), in combination with chemotherapy for the first-line treatment of locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) in adults whose tumors express PD-L1 (Combined Positive Score [CPS] of at least 10) and who have not received prior chemotherapy for metastatic disease.

The approval is based on final analysis from the Phase III KEYNOTE-355 trial, in which Keytruda in combination with chemotherapy (nab-paclitaxel, paclitaxel or gemcitabine/carboplatin) significantly improved overall survival (OS), reducing the risk of death by 27% (HR=0.73 [95% CI, 0.55-0.95]; p=0.0093), and progression-free survival (PFS), reducing the risk of disease progression or death by 34% (HR=0.66 [95% CI, 0.50-0.88]; p=0.0018) compared to chemotherapy alone in these patients. In this trial, 38% of enrolled patients had tumors expressing PD-L1 with CPS of at least 10.

Condition: Breast Cancer Triple Neg
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.